Improving the lives of people with neurological health conditions

Hyasynth is an innovative Series A biopharma venture that's transforming how therapeutic cannabinoids are produced and accessed. Founded by Kevin Chen, Zack Wiltshire, Shoham Mookerjee, and Alex Campbell, Hyasynth exemplifies cutting-edge innovation in the bio sector.

‍

The Innovation

Hyasynth has developed a groundbreaking method to produce cannabinoids using yeast through industrial fermentation, creating a more scalable, efficient, and sustainable alternative to traditional approaches. This innovative solution:

• Offers advantages over conventional chemical synthesis methods
• Provides an alternative to resource-intensive cannabis cultivation
• Addresses growing demand for cannabinoids used in medical treatments
• Enables consistent pharmaceutical-grade production

‍

Advancing Therapeutic Solutions

The company's technology directly impacts the lives of people suffering from various conditions, as cannabinoids are increasingly recognized for their therapeutic potential in treating:

• Epilepsy
• Chronic pain
• Other neurological conditions

Importantly, these alternatives can help reduce reliance on opioids, addressing a critical public health challenge.

‍

Scientific Excellence

The co-founders, experts in yeast genetic engineering, have successfully created specialized yeast strains that produce cannabinoids at a large scale. Their approach leverages industrial fermentation—a widely established manufacturing process already used in food and pharmaceutical industries.

This scientific breakthrough promises to deliver cannabinoids that are:

• Rare or difficult to extract from natural sources
• Novel compounds with unique therapeutic properties
• Consistently pure and pharmaceutical-grade

‍

Strategic Partnerships

Hyasynth has formed key strategic relationships to accelerate commercialization, including a partnership with Organigram, a major player in the cannabis sector. The company is actively working to establish global connections with researchers and companies aligned with their mission.

Sustainable Vision

"Our aim is to make a sustainable and reliable supply chain for these unique products." — Hyasynth Team

‍

Transforming Biopharma Through Innovation

Hyasynth represents how District 3's ecosystem supports ventures at the intersection of biotechnology and healthcare. By developing sustainable production methods for therapeutic compounds, they're helping create more accessible treatments while demonstrating how scientific innovation can address both patient needs and environmental considerations in the biopharma space.

‍